Friedreich S Ataxia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for friedreich s ataxia. 7 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
7
Active US patents
43/100
Avg vulnerability
$300M
Annual revenue covered

Originators in Friedreich S Ataxia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Biogen Us 7 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating friedreich s ataxia. Each bar = one year. Y-axis scaled to peak year (5 patents).

5
29
2
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Skyclarys
OMAVELOXOLONE
 Biogen Us 7 43 $300M 2029-04-20

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11919838 Skyclarys method of use 88 2029-04-20
11091430 Skyclarys method of use 83 2029-04-20
8440854 Skyclarys formulation 63 2029-04-20
9670147 Skyclarys composition of matter 25 2029-04-20
8124799 Skyclarys composition of matter 18 2029-12-03
8993640 Skyclarys composition of matter 12 2033-04-24
9701709 Skyclarys composition of matter 12 2033-04-24

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8993640 Skyclarys composition of matter 12 2033-04-24
9701709 Skyclarys composition of matter 12 2033-04-24
8124799 Skyclarys composition of matter 18 2029-12-03
9670147 Skyclarys composition of matter 25 2029-04-20
8440854 Skyclarys formulation 63 2029-04-20
11091430 Skyclarys method of use 83 2029-04-20
11919838 Skyclarys method of use 88 2029-04-20

Related